Announcements Trials
Browse Landscape

Phase

Phase 1 4

Status

Completed 2Terminated 1Recruiting 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Other solid neoplasm 4

Conditions

Carcinoma, Non-Small-Cell Lung 8Uterine Cervical Neoplasms 4Stomach Neoplasms 4Squamous Cell Carcinoma of Head and Neck 4Advanced Solid Tumors 4Lung Neoplasms 3Carcinoma, Renal Cell 3Urinary Bladder Neoplasms 2Solid Tumor 2Ovarian Neoplasms 2Neoplasms 2Melanoma 2Esophageal Neoplasms 2Colorectal Neoplasms 2Adenocarcinoma Of Esophagus 2Triple Negative Breast Neoplasms 1Solid Tumors 1Solid Tumor, Unspecified, Adult 1Recurrence 1Prostatic Neoplasms, Castration-Resistant 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Multiple Myeloma 1Metastatic Urothelial Cancer 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Kidney Neoplasms 1Erythrocytosis, Familial, 4 1Endometrial Neoplasms 1Carcinoma, Merkel Cell 1

Interventions

Injections 25Carboplatin 17Docetaxel 14pembrolizumab 12Paclitaxel 11Bevacizumab 9durvalumab 8Cisplatin 8Nivolumab 6Fluorouracil 6trifluridine tipiracil drug combination 5tislelizumab 5linifanib 5Pemetrexed 5Oxaliplatin 5Leucovorin 5zimberelimab 4toripalimab 4talazoparib 4olaparib 4Itraconazole 4Irinotecan 4Gemcitabine 4Capecitabine 4tremelimumab 3sotorasib 3sintilimab 3fludarabine 3depatuxizumab 3atezolizumab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
INDUSTRY × Advanced Solid Tumors × zimberelimab × Clear all
NCT06532565 2026-04-21

Study of GS-2121 Given Alone or in Combination in Adults With Advanced Solid Tumors

Gilead Sciences

Phase 1 Recruiting
154 enrolled
Other solid neoplasm

Advanced Solid Tumors

NCT04087018 2024-09-19

Study to Evaluate Safety and Clinical Activity of AB122 in Biomarker Selected Participants With Advanced Solid Tumors

Arcus Biosciences, Inc.

Phase 1 Completed
18 enrolled
Other solid neoplasm

Advanced Solid Tumors

NCT04747470 2024-09-03

Study to Assess the Effects of GS-3583 in Participants With Advanced Solid Tumors

Gilead Sciences

Phase 1 Terminated
13 enrolled 18 charts
Other solid neoplasm

Advanced Solid Tumors

NCT03713905 2023-04-10

Study of Recombinant Human Anti-PD-1 Monoclonal Antibody for Patients With Advanced Solid Tumors

Guangzhou Gloria Biosciences Co., Ltd.

Phase 1 Completed
293 enrolled
Other solid neoplasm

Advanced Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡